Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China

BackgroundProgrammed death receptor 1 (PD-1) inhibition has shown durable response and mild adverse events (AEs) in adult malignancies. However, data on the clinical activity of PD-1 inhibition in pediatric patients are lacking. We comprehensively assessed the efficacy and safety of PD-1 inhibitor-b...

Full description

Bibliographic Details
Main Authors: Ye Hong, Mengjia Song, Yingxia Lan, Juan Wang, Suying Lu, Yu Zhang, Jia Zhu, Feifei Sun, Junting Huang, Juan Liu, Jiaqian Xu, Yanpeng Wu, Haixia Guo, Ruiqing Cai, Zijun Zhen, Yi Que, Yizhuo Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
pediatric malignancies
PD-1 inhibitors
PD-1 inhibitor-based treatment
safety
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182751/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182751/full

Similar Items